Femasys’ (FEMY) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Femasys (NASDAQ:FEMYFree Report) in a research report released on Thursday, Benzinga reports. They currently have a $13.00 price target on the stock.

Other equities research analysts have also issued research reports about the stock. Chardan Capital restated a buy rating and issued a $12.00 target price on shares of Femasys in a report on Monday, April 1st. Jonestrading increased their target price on shares of Femasys from $7.00 to $10.00 and gave the company a buy rating in a research report on Wednesday, March 20th.

Get Our Latest Report on Femasys

Femasys Stock Performance

Shares of FEMY opened at $1.15 on Thursday. The company has a current ratio of 8.43, a quick ratio of 8.02 and a debt-to-equity ratio of 0.29. The stock has a market capitalization of $25.55 million, a P/E ratio of -1.37 and a beta of -2.79. The firm’s fifty day simple moving average is $1.22 and its two-hundred day simple moving average is $1.24. Femasys has a 12 month low of $0.25 and a 12 month high of $4.75.

Femasys (NASDAQ:FEMYGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.05. The company had revenue of $0.27 million for the quarter, compared to analysts’ expectations of $0.30 million. Femasys had a negative net margin of 1,420.59% and a negative return on equity of 104.06%. As a group, analysts predict that Femasys will post -0.72 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Femasys stock. Barclays PLC purchased a new stake in Femasys Inc. (NASDAQ:FEMYFree Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 99,003 shares of the company’s stock, valued at approximately $295,000. Barclays PLC owned 0.66% of Femasys at the end of the most recent reporting period. Institutional investors and hedge funds own 65.27% of the company’s stock.

About Femasys

(Get Free Report)

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.

Featured Stories

Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.